Engineering and Characterization of Fn3 Proteins that Recognize Mesothelin Tumor Biomarker for Targeted Cancer Therapeutics

We are developing molecules for the targeted treatment of cancer and measuring their anti-cancer effects. We are further engineering the proteins to create protein-drug conjugates.

Engineering and Characterization of Fn3 Proteins that Recognize Mesothelin Tumor Biomarker for Targeted Cancer Therapeutics; poster session deriving from special studies, and honors thesis research with Sarah Moore, associate professor of engineering, and Alexis Ziemba, lecturer of neuroscience